A number of other analysts also recently commented on CRSP. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Finally, Canaccord Genuity lifted their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a report on Wednesday, November 20th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $75.95.
NASDAQ:CRSP traded down $1.16 during midday trading on Friday, reaching $53.59. 837,212 shares of the company traded hands, compared to its average volume of 1,095,512. The company has a fifty day moving average price of $62.10 and a 200 day moving average price of $52.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -116.50 and a beta of 3.20. Crispr Therapeutics has a twelve month low of $29.34 and a twelve month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, equities research analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 in the last 90 days. Corporate insiders own 21.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. BNP Paribas Arbitrage SA acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $41,000. Aperio Group LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $153,000. Trexquant Investment LP acquired a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $466,000. LPL Financial LLC raised its holdings in Crispr Therapeutics by 303.6% in the 2nd quarter. LPL Financial LLC now owns 33,298 shares of the company’s stock valued at $1,568,000 after acquiring an additional 25,047 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Crispr Therapeutics by 116.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares in the last quarter. Institutional investors own 49.84% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.